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ABSTRACT

Concurrent Engineering and Design for Manufacture
in the Medical device Industry

by
Martin A. Mathelier

Concurrent Engineering (CE) is an approach to product development in which
engineers work on design and manufacturability at the same time. The ultimate
goal of concurrent engineering is to reduce the time-to-market while improving
quality. This thesis goes into details about the tools necessary to achieve successful
product development in the Medical Device Industry. The novelty of this thesis is
not in the tools themselves but rather in the way that they are applied to the
medical device industry. The need for the CE approach is of utmost importance
because of the vast competition in the medical device industry.
The times now require changes. These changes are depicted in detail early in
this thesis. This latter suggests that manufacturing is to be perceived like another
science. The axiomatic approach to manufacturing answers these needs. A new way
of designing a product and collecting data is relevant. It is known as the technique
of Quality function Deployment (QFD). Finally, all these tools are managed with
the phase approach to management. I sincerely think that this thesis will constitute
an invaluable tool for managers and engineers in the medical industry.
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CHAPTER 1

INTRODUCTION

1.1 The Purpose of Concurrent Engineering
A classical definition of Concurrent Engineering (CE) is the earliest possible
integration of a company's overall resources, knowledge, experience in design,
development, manufacturing and sales. The basic idea is to create successful new
products with high quality and low cost while meeting the customer expectations.
The most desirable result of using CE is to shorten the product life development
cycle. The product concept, design and development process should be parallel
instead of sequential.
In the medical device industry, the current manufacturing system method used
to achieve shorter product development cycle is the changing of part drawings their
tolerances and the modification of existing line-ups. The aforementioned system
updates documentation such as part lists, configurations and assembly drawings.
This method also reworks the tooling and renegotiates with the component's
suppliers. After the product is on the market, the Marketing and Quality Assurance
groups report customer complaints on product use and performance against the
advertised specifications.
In many cases these reports are usually distributed throughout the organization.
The current system does not provide for a product champion initiating a new
venture to learn from the previous product manager's mistakes. Communication
links are not established to make the design and development departments aware
of previous deficiencies. Those deficiencies should not be in the next generation
of the product. Figure 1 illustrates all the information that should be readily
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Figure 1

Concurrent Engineering Chart
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available for each product in the company catalog. All this information (Device
Master Listing - a matrix where all the specifications and all Drawings are listed,
Bill of material, Marketing information, Equipment selection, Material election)
would prevent the product developers from solving the same problem a number of
times. The availability of this information would put the developer in a good
starting position. In turn, the development cycle time would be reduced
considerably.
At present, only one section of the aforementioned chart (The Device Master
Listing Section) is available in the development of a new product. The proposed
CE integration method can be implemented using the tool of Design For
Manufacture (DFM) discussed later in this thesis. Also, the crucial importance of
the functional attributes of a design in the medical device industry was causing the
designer often to neglect the axiomatic approach to manufacturing. This approach
is discussed later in this thesis. It is simply a set of rules forcing the Designer to
make correct manufacturing decisions early in the design process. The need to
reduce development time was not a problem until recently, when competition began
to increase in the medical device market. One of the problems is that many
companies do not have the managements skills, the resources or tracking system
necessary to identify these deficiencies.
The new products have the same level of customer satisfaction quality as the
previous one. The cause is that engineers are solving the same problems for every
new product. Most companies in the medical device industry do not have a
structured phase implementation system in the development of a new product. The
activities to developed a new product are not structured in the most efficient
manner. The order that the process steps are done varies from one project
engineer/manager to another. Of course, in a few cases the manager is
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knowledgeable of the new Concurrent Engineering techniques available. In those
limited cases, successful product are produced. The point is that companies that are
currently producing successful products in a short amount of time are mostly doing
so because of the skills of their managers, not because of a system in place. The
solution to this imbalance, is to have a well structured system where anybody in
this industry should be able to follow a set of standardized steps to come up with
a successful product in a relatively short time. The trained individual only has to
follow the guidelines that this thesis illustrates.
As of now, even though there exists competition in the medical device
industry, it is not as rigorous as in the other industries such as the automobile,
electronics and appliances industries. The regulations of the Federal Drug
Administration to enter this market are very strict. Nevertheless, only the company
willing to use the new DFM and CE technique will remain the major player in the
Medical Device industry. In the worldwide and domestic competitive arena,
companies have to react quickly with new products in order to respond to customer
trends, technological advances and competitors products. Medical Device
companies need new products to continue to grow by opening new markets,
creating new customer demand and increasing their market share.
The key to success in this industry is a company's ability to create new
products quickly by doing development manufacturing and delivering customer
satisfaction "right the first time". A point of importance is that due to the nature
of this industry the release of a badly designed product could be detrimental to the
entire organization. The medical device industry deals with human life. The
designer has only one chance to make the best product to meet patients needs.
Concurrent Engineering can play a significant role in the effective realization of
this aim. The techniques and tools of CE concentrate on the product concepts in
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order to meet market and customer desires and reduce the time and iterations of
new product development. This is achieved by producing prototypes that are made
to specifications and meeting the company's manufacturing requirements.
The tools and techniques of Concurrent Engineering were used first in world
class companies like Ford, AT&T and Hewlett Packard. All these ideas have
become well established and are proven to be successful in many instances.
Hewlett Packard has the highest number of new successful products in the past two
years. This thesis focuses on applying those well established concepts to the
medical device industry. It is predicted that unless a company is willing to adopt
those new techniques it will not be able to stay in business.
In the implementation of Concurrent Engineering in the medical device
industry, the values of teamwork, the sharing of ideas and their goals beyond their
immediate assignment and departmental loyalty are of imperative importance.The
successful new product interdisciplinary teams are the ones that are focused on
aggressive but achievable goals for CE and DFM. The characteristics of teamwork
and cooperation can be rewarded by making them an integral part of the
performance evaluation process for engineers.
One of the most important elements in understanding the complexities of
introducing new products is the use of the tools of structured analysis to describe
the different processes and information flow inherent in a complex medical device
plant. The structure chart methodology, which was developed for the software
industry, can be used here to describe and clarify those processes.

1.2 The Importance of Upper Management Involvement
For Successful CE & DFM Implementation
A important part in the implementation of CE and DFM in the medical device
companies is the acknowledgment that CE and DFM are important parts of the
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company's competitive strategy. Concurrent Engineering and Design For
Manufacturing should be included in the goals and objectives of the entire
organization. Each group should have its own strategy matching the overall
company plan. Upper management should be convinced that the application of
Concurrent Engineering will result in selecting the best opportunities for
development. This system will make developing competitively successful products
easy. It will achieve more rapid time to market and will increase development
productivity. Achieving world class product development using CE will increase
revenue and profit. The key benefits are:
1) The reduction in cycle time (cost saving, increased revenue).
2) The product will match the customer's expectations.
3) The products will be designed better (cost saving, increased profit).
4) There will be better overall development.
5) There will be greater global coordination (for worldwide companies having
manufacturing sites and distribution centers throughout the world).
6) A new generation of rapid response development process.
The institution of a Concurrent Engineering program requires serious
commitment from every level of management. It also requires and a close look at
the design, engineering and manufacturing process. Managing the proposed change
in a medical device company will require careful planning to ensure success. The
practice of CE and DFM should not belong to a specific group but should be
shared among all. The role of the company management is to understand the
implication of Concurrent Engineering. An example would be a longer initial
development cycle with a reduction of the overall cycle for the entire project in
question. Another illustration would be the measurement and continuous
improvement of the current levels of product cost, testability, quality, reliability and
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serviceability. It is also important that management understand the issues of
Concurrent Engineering. Management should set operational goals and measures
that are in line with the current product design and development practice. In
establishing a new product development strategy it is imperative that each
Concurrent Engineering plan and goal be clearly outlined. The goal statements and
plans of action should be formulated with the cooperation of all appropriate
departments. The milestone and checkpoint (describe as phases in the proposed
solution) for new products should contain progress updates on Concurrent
Engineering goals. Another important role of upper management is to support
engineering suggestions of proposing long-range capital and process developments
in the company.
The long range plans of manufacturing and information flow should be in line
with plans for new products technologies. One ►major role of upper management
should be to support appropriate departments in implementing credible concurrent
engineering plans such as documenting process capability for the manufacturing
process, determining the current level of warranty cost for the quality department
and planning the service level for future products. Finally after a new product is
released, production management should perform a retrospective analysis to
compare actual results of the product performance after release to production with
the original development project goal. The reasons for success or failure should be
documented so the information can be fed back to new projects.

1.3 Design for Manufacture (DFM) Concept
Design For Manufacture (DFM) represents a new awareness of the importance of
design as the first manufacturing step. As done in all the other industries including
the automobile industry, the electronics industry and the appliance industry, the
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medical device industry has to recognize that they will not meet quality and cost
objectives with isolated design and manufacturing engineering operations. To be
competitive in today's medical device marketplace requires a single engineering
process from concept to production. The essence of the DFM approach is the
integration of product design and process planning into one common activity. The
DFM approach embodies certain underlying imperatives that help maintain
communication between all components of manufacturing system and permit
flexibility to adapt and to modify the design during each stage of the product's
realization. The key among these is the team approach to simultaneous engineering,
in which all relevant components of the manufacturing system including outside
suppliers are made active participants in the design effort from the start. The team
approach helps ensure that total product knowledge is as complete as possible at
the time each decision is made.
Other imperatives include a general attitude that resists making irreversible
design decisions before they absolutely must be made and a commitment to
continuous optimization of product and process. The objectives of the Design For
Manufacture approach are to identify product concepts that are inherently easy to
manufacture to focus on component design for ease of manufacture and assembly,
and to integrate manufacturing process design and product design to ensure the best
matching of needs and requirements. Meeting these objectives requires the
integration of an immense amount of diverse and complex information. This
information includes not only considerations of product form, but also the
organization and administrative procedures that underlie the design process.
Because of the complexity of the issues involved , it is convenient to divide the
subject of DFM into two considerations:
1) The DFM approach or process by which a product can be effectively designed
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for manufacture and
2) The methodologies and the tools that can be used to help enable the DFM
approach and to help ensure that the physical design meets the DFM objectives.
The proposed version of DFM to be used in the medical industry can be
illustrated in figure 2. The four activities comprising this process are arranged in
a circular fashion to emphasize the iterative nature of the process. Traditionally,
many products have been designed by starting with functional optimization of the
product design itself followed by detail design of each part to be made by a
particular process, then simplification and finally design of a process to
manufacture and assemble the product. As shown by the arrows, the progression
of steps in the proposed DFM process is the reverse of the more traditional design
approach.
The DFM process begins with a proposed process concept, and a set of design
goals. All three of these inputs would be generated by a thorough product plan
developed using the team approach. Design goals would include both
manufacturing and products goals. Each activity within the DFM process addresses
a particular aspect of the design. Optimization of the product/process concept is
concerned with integrating the proposed product and process plan to ensure
inherent ease of manufacture. The simplification activity focuses on components
design for ease of assembly. This activity can often be rapidly effective because the
integrated product and process requirements and constraints help to identify
problem areas. The third activity ensures conformance of the design to processing
needs. Finally functional optimization considers appropriateness of material
selection and parameter specifications that maximize the design objectives. By
reversing the process, the DFM approach helps ensure that all of the design
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Figure 2 DFM Process

II
constraints, including assembly, material transformation processes, and material
handling requirements are included as part of the functional optimization of the
design.
In this, the DFM process enables the design team to consider all aspects of the
product's design and manufacture in the early stages of the design cycle, so that
design iteration and accompanying engineering changes can be made easily and
cost effectively. Finally, by integrating the product and process design, it is
possible to include manufacturing recommendations and a process plan as part of
the engineering release package. This has great advantages because it leads to few
or no manufacturing surprises. Also both manufacturing and engineering share
equally in ownership of the ultimate commitment to the design.
The development and use of design methodologies that help the design team
achieve an optimized design solution is an important part of the DFM approach.
Table 1 provides a selected list of DFM methodologies and tools and indicates
where they might fit into the proposed DFM process. Use of these design
methodologies helps promote the objectives of DFM by guiding the design team
in making better informed design decisions and providing systematic procedures
that help ensure that all aspects of product function manufacture and operational
support are considered from the start. For the medical devices industry the DFM
design tools that are suggested because of the criticality of functional requirements
are as follows: the Axiomatic theory of design, the DFM guidelines, the
manufacturing process design rules and computer-aided DFM. A total evaluation
of the aforementioned tool of DFM in the medical device industry will show the
benefits of this new way of manufacturing.
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Table 1 DFM TOOLS

Design
axiom
DFM
Guide.
DFA
Method
Taguchi
Method
Mfg
Process
Design
Toolkit
CAD
DFM
Group
Tech.
Fmea
Value
Analysis

Optimize
Concept

Simplify

Process
Conformance

⃞

•

⃞

•

0

Product
Function

0
⃞

⃞
⃞

⃞
⃞

⃞

⃞

⃞

⃞

•

⃞

⃞
⃞

⃞
⃞

I3
1.3.1 The Meaning of DFM in The Medical Device Industry
In the medical device industry, Design for Manufacture (DFM) means different
things to different people. For the designer whose task is to consider the design of
a single component, DFM means the avoidance of component features that are
unnecessary expensives to produce. Examples include the following: Specification
of the surface to be smoother than necessary on a machined component
necessitating additional finishing operations; Specification of wide variations in the
wall thickness of an injection molded component; Specification of too-small fillet
radii in a forged component. Alternatively, the DFM of a single component might
involve minimizing material costs or making the optimum choice of materials and
processes to achieve a particular result. For example, can the component be cold
headed and finish-machined rather than machined from bar stock? All of these
considerations are important and can affect the cost of manufacture. They represent
only the fine-tuning of costs, however, and by the time such considerations are
made, the opportunities for significant savings may have been lost. It is important
to differentiate between component or part DFM and product DFM. The former
represents only the fine-tuning process taken under once the product form has been
decided upon without compromising the functionality. The latter attacks the
fundamental problem of the effect of product structure on total manufacturing costs.

1.3.2 Design for Assembly (A Key Attribute of DFM)
Another key to successful product DFM is product simplification through Design
for Assembly (DFA). DFA technique primarily aim to simplify the product
structure so the assembly cost are reduced. Experience shows that the consequent
reduction in part costs often far outweigh the assembly cost reductions. Even more
important, the elimination of parts as a result of DFA has several secondary
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benefits more difficult to quantify, such as improved reliability and reduction in
inventory and production-control costs. DFA, therefore, means much more than
design to reduce assembly costs and in fact is central to the issue of product DFM.
In other words, part DFM is only icing on the cake; product DFM through DFA
is the cake.
DFA derives its name from a recognition of the need to consider assembly
problems at the early stages of design. It therefore entails the analysis of both
product and part design. For some years now an assembly evaluation method has
been in use at Hitachi. In this proprietary method, commonly referred to as the
Hitachi method, assembly element symbols are selected from a small array of
possible choices. Combinations of the symbols then represent the complete
assembly operation for a particular assembly operation for a particular part. Penalty
points associated with each symbol are substituted into an equation, resulting in a
numeral rating for the design. The higher the rating the better the design.
Another quantitative method involves two principal steps: 1) The application
of criteria to each part to determine whether, theoretically, it should be separate
from all the other parts in the assembly, an 2) an estimate of the handling and the
assembly costs for each part using the appropriate assembly process. The first step,
which involves minimizing the part count, is the most important. It guides the
designer toward the kind of product simplification that can result in substantial
savings in product costs. It also provides a basis for measuring the quality of a
design from an assembly point of standpoint. For instance, in the design of a blood
containment device at Becton Dickinson & Co., the design team in cooperation
with Manufacturing came up with the best design for manufacture where all the
components snapped into place. During the second step, cost figures are generated
that allow the designer to judge whether suggested design changes will result in
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meaningful savings in assembly cost.
For business reasons, most medical device companies are seldom prepared to
release their manufacturing cost information. One reason is that many companies
are not sufficiently confident about their costing procedures to want manufacturing
costs made public for general discussion. In such an environment, the designer of
a medical device product will often not be informed of the cost of manufacturing
the product that they have been designing. Moreover, engineers and designers do
not have the tools necessary to obtain immediate cost estimates relating to
alternative product design schemes. Typically, a product will been designed and
detailed and a prototype manufactured before a manufacturing cost estimate is
attempted. Unfortunately, by then it is too late. The opportunity to consider
radically different product structures has been lost, and among those design
alternatives might have been a version that is substantially less expensive to
produce.
Currently, there is much interest in the medical device industry in having
product DFM and DFA techniques available on CAD/CAM systems. By the time
a proposed product design has been sufficiently detailed to enter it into the
CAD/CAM system, however, it is already too late to make radical changes. A CAD
representation of a new product is an excellent vehicle for making effortless details
changes, such as moving holes and changing draft angles. But for considering
product structure alternatives, such as the choice of several machine parts versus
one die casting, a CAD system is not nearly as useful. These basic, fundamentally
important decisions must be made at the early sketch in product design. A conflict
thus exists. On the one hand, the designer needs cost estimates as a basis for
making sound decisions. On the other hand, the product design is not sufficiently
firm to allow estimates to be made using currently available techniques. The means
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of overcoming this dilemma is another key to successful product DFM -namely
early cost estimate. Now some Japanese companies are even establishing their
target cost prior to designing the product.

1.4 Concurrent Engineering as a Competitive Advantage
The fact that these CE and DFM methods will bring product to market in a shorteramount of time than the conventional method of manufacturing gives the company
a competitive edge. This method could be compared to a force multiplier except
for this one three times the resources of the adversary (the competitor) is not
necessary to be successful. Moreover, throughout the years, attributes such as
quality, cost containment and shorter time to market has given many companies an
edge on their competition. Concurrent Engineering and Design For Manufacture are
the ways to conquer this very difficult market and to stay on top.
Because of diminishing product life cycles and rapid technological
advancements, few firms can afford to adapt their manufacturing technology to the
production needs of each new product. And because of increasing consumersophistication and competitive pressure, still fewer medical device companies can
afford to skimp on quality to avoid manufacturing trouble. That is the reason that
in order to remain competitive, medical device companies are now turning to
Concurrent Engineering and DFM methods to streamline production process and
achieve high quality, low cost product.

1.5 Concurrent Engineering Strategies and Benefits
in the Medical Device Industry
The first concurrent engineering effort in a medical device company is the
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Figure 3 Core Team

Figure 4 Product Proposal
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formation of an interfunctional and interdisciplinary core team (figure 3) and an
approval committee to facilitate new product development. The purpose of the team
is to shorten the product development cycle, improve product reliability, and
reduce cost through Concurrent Engineering and Design For Manufacture. At that
point, it is desirable to set specific goals (a product proposal figure 4) for the
effort. These goals should be aggressive but realistic for the company and should
be based on the performance of current products. The strategy should be to
combine the connectivity of CAD with the Design For Manufacturing and to get
manufacturing involved early in the design of the product. The strategy's elements
could be: a) Document the current manufacturing process capabilities and
constraints. Structured analysis and data flow diagrams should be generated for the
production processes and reviewed by the respective departments for elimination
of redundant tasks and verification of the current process b) Have a data base
where all information about a product can be stored; starting from conception to
end. This would greatly reduce the development time and improvements could be
implemented for a similar new product. c) Review all new parts and use DFM tool
for the design of a new product. d) Use and develop software tooling whenever
to allow manufacturing to build all prototypes. Manufacturing should treat
prototypes as the highest priority of production.

CHAPTER 2

THE AXIOMATIC APPROACH TO MANUFACTURING

2.1 Definitions of Terms
The axiomatic approach that was mentioned earlier in this thesis will contribute a
methodology for optimization of the manufacturing system in the medical device
industry. The term axiom is used here in the same general sense as thermodynamic
axioms, which provide basic guidelines to the study of thermodynamics.
Specifically, an axiom is a proposition which is assumed to be true without proof
for the sake of studying the consequences that follow from it. Manufacturing
axioms should provide reference guidelines, which force decisions toward
optimization of the entire manufacturing system when followed. Strictly speaking,
an axiom must be a general truth, that is, a rule for which no exceptions or
counter-examples can be observed. Similarly, an axiom cannot be proven, rather
it must be assumed to be true until a violation or counter example can be found.
An axiom must be general. For a manufacturing axiom to be useful, it must be
applicable to the full range of manufacturing decisions. By implication, there
should be a relatively small number of manufacturing axioms.
The term corollary is used here also in the mathematical sense. A corollary is
an immediate or easily drawn consequence of an axiom or set of axioms. In
contrast to axioms, corollaries may pertain to the entire manufacturing system, or
may concern only a part of the manufacturing system.

2.2 Description of the Axiomatic Approach to Manufacturing
The first step in the axiomatic approach to "optimization" of a manufacturing
20
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system is the specification of the functional requirements of the end product ( for
example the delivery of serum through syringe). The determination of functional
requirements is discussed in Ellinger and Glegg at some length. Functional
requirements are defined here as a minimum set of independent specifications that
completely define the problem. Other examples of functional requirements are:
kinematic and load requirements, expected life under a given set of temperatures,
pressures and environment, efficiency, input power, etc. Functional requirements
can be ordered in a hierarchial structure, starting from the primary functional
requirement to the functional requirement of least importance.
In addition to these functional requirements, there may be the need to specify
constraints. Constraints are defined as those factors which establish the boundaries
on acceptable solutions. Constraints on the product may be in form of either
acceptable cost, OSHA requirements or adaptability to existing systems. The
difference between functional requirements and constraints is that functional
requirements are negotiable final characteristics of a product, while constraints are
not.
Once functional requirements and constraints are specified in a given product,
the design of the product can proceed concept. During each stage of realization of
the product, axioms can be to make decisions. Each decision must be guided by
axioms and corollaries and must not violate them. A product designed by
following the axioms, should yield a design which can be made more productively
than otherwise. Similarly, the functional requirements constraints may be specified
for manufacturing process and manufacturing process ►may be synthesized following
a set of axioms again yielding maximum productivity for that specified product.
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2.3 A Methodology for Developing Manufacturing Axioms
As described earlier, axioms have two fundamental characteristics:
1. They cannot be proven.
2. They are general truths; no violations or counter examples can be observed.
These characteristics naturally suggest a heuristic approach in development of
axioms. The heuristic approach involves a positive initial set of axioms. Untested
and untried, these "hypothetical" axioms can then be subjected to trial and
evaluation in manufacturing case studies. The extent to which these hypothetical
axioms affect the requirements for true axioms can be assessed. The evaluations
can be used to expand, redefine and refine the original set of axioms. The process
converges on a comprehensive set of axioms.

2.3.1 Hypothetical Axioms
To begin an axiomatic approach, a starting set of axioms must be stated. They are
intended for use in the design of a product on processing and production. They are
therefore stated as direct rather than as observations.
Axiom 1. Minimize the number of functional requirement constraints.
Axiom 2. Satisfy the primary functional requirement first. Save the others in
order of importance.
Axiom 3. Minimize information content.
Axiom 4. Decouple or separate parts or aspects of a solution functional
requirements are coupled or become interdependent to the designs or
processes proposed.
Axiom 5. Integrate functional requirements in a single positive solution if they
can be independently satisfied in the proposed solution.
Axiom 6. Everything being equal conserve materials.
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Axiom 7. There may be several optimum solutions.

2.3.2 Corollaries
A large number of corollaries with more specific applications can be derived from
the basic axioms. Eight are derived here for illustrative purposes.
Corollary 1.

Part count is not a measure of productivity.

Corollary 2.

Cost is not proportional to surface area.

Corollary 3.

Minimize the number and complexity of part surfaces.

Corollary 4.

If a solution satisfies more independent functional requirements
and constraints than were originally imposed, the part or
process may be overdesigned.

Corollary 5.

A part should be a continuum if energy conduction is
important.

Corollary 6.

If weaknesses cannot be avoided, separate parts.

Corollary 7.

If secondary functional requirements can be satisfied without
violating primary requirements then integrate.

Corollary 8.

Use standardized or interchangeable parts whenever possible.

The first of these arises out of axioms 4 (decouple to retain independence) and
5 (integrate where independence is maintained). Since axiom 4 increases part
count while axiom 5 decreases it while both increase productivity, clearly part
count alone contains no information about productivity. Axiom 3 (information)
prevents a needless proliferation of parts.
Corollary 2 arises from the axioms constraining information (3) and material
(6). Surface area measures neither mass nor information content and thus has little
effect on productivity.
Corollary 3 follows from axiom 3, minimize information, and often from axiom
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1 (minimize requirements and constraints) when a part is serving too many
functions.
Corollary 4 is a consequence of axioms 1 and 7 dealing with minimizing
functional requirements and constraints and the plurality of optimum solutions. It
states the "no such thing as a free lunch" philosophy. If you are getting more than
you need, you are probably paying for it.
Corollary 5 (continuum for energy conduction) results from axiom 5 (integrate).
If two parts are to conduct energy in some form (heat, electricity, sound, light, etc)
it is advantageous to make them one part to avoid contact resistance or reduced
transmission. Axioms 1 and 2 avoid misuse of this corollary where functional
requirements other than energy transmission are concerned.
Corollary 6 on avoiding weakness is derived from axiom 4 (decouple to avoid
function dependence). If an "O"-ring grove provides a sealing function but
weakens a structure, dividing the structure at the groove may reduce stress
concentration by moving the stress elsewhere. It is assumed that other axioms are
not violated in so doing.

2.4 Disavantage of the Axiomatic Approach to Design
Many experts in the medical device industry are proposing rule-based or axiomatic
approach to product design. As describe above the axiomatic approach as applied
to the medical device design is based on attempts to identify common properties
of successful designs. These common properties such as how the design satisfies
the functional requirements, were then proposed as axioms of good design. Design
axioms can thus be viewed as global product guidelines that can co-exist with
component guidelines for details such as hole spacings, fillet radii and draft angles.
However, axiomatic approaches have two major weakness when manufacturing
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is considered in the early stages of product design. Both of these weakness are
directly related to cost. First the aforementioned approach does not provide any
means of making judgments between the centrally important tradeoffs posed by
possible alternative choices of different materials and processes. Second, at the
detail level, guidelines tend to lead designer in an essentially fruitless direction.
This is because manufacturing guidelines are invariably intended to make individual
processing steps as efficient as possible. Following such guidelines might lead to
the avoidance of side hole or depressions in molded parts, the minimization of the
number of steps in a part to be made by EDM machining it and so on. With this
approach, the tendency is to design relatively simple individual components, which
will invariably lead to high total fabrication and assembly costs.
The axiomatic approach is recommended but a designer working in a medical
environment has to put the functional requirements as primordial concerns.
Ultimately a DFM system must therefore must be able to predicts assembly cost,
functionality requirement, and component manufacturing costs at the earliest stages
of product design. Only in this way will it be possible to the design a product that
takes maximum advantage of the capabilities of chosen manufacturing processes
within the constraints imposed by functionality. In many situations this will simply
mean providing the designer or design teams with the software tools that will
enable them to make sound decision from a range of choices. These choices may
involve designs necessitating increased tooling but fewer different parts and
reduced assembly cost.

2.5 Rating of a Product Using DFA Tools
It is anticipated that medical device product DFM considerations will always start
with DFA. To aid designers in implementing these techniques, many software have
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been developed for to the medical device manufacturing market to establish an
efficient assembly sequence for a proposed new product concept. The software then
question the relationship between the parts and give an assembly efficiency rating,
together with estimated assembly cost. The DFA process uses the assembly
sequence as a vehicle for analyzing the product structure in order to force the
design toward more integrated solutions with a reduced part count. This result of
DFA is often the most important one in achieving total cost reductions. Thus, DFA
analyses must be supported by techniques that will allow the design team to make
early estimates of material, processing and tooling costs. Only in this way can
designs, with different numbers of parts and perhaps using different materials and
processes, be compared before detailed commitment is made.
The results of this DFA analysis, combined with early cost estimating methods,
illustrate the kind of result that can be obtained by using DFA as the first step in
a product DFM study. Of course, it is possible to achieve savings by considering
changes in product design that are directed at reductions in individual part costs.
The techniques of DFA and DFM can play a major role in reducing costs and
increasing productivity in the design of a medical product. Recognition of this fact
is also increasing the demand for cost estimating tools that allow design teams to
make the necessary tradeoffs at the early concept stages of design. These technique
and tools can play a significant part in helping US industry to keep its supremacy
in the medical device industry.

CHAPTER 3

FDA REGULATIONS AND CONSTRAINTS

3.1 Medical Device Technology in General. An Overview of
Products and The Industry
For the purpose of understanding the urgency of shorter development cycle, it is
important to establish a clear definition of the medical device technology. Referred
to as one of the country's more innovative industries, U.S. Medical device
technology has been the focus of increasing attention in recent years. The reasons
are many: the industry has produced significant new medical advance, from fiber
optics to diagnostic imaging; it has become a world leader in medical product sales,
contributing to $4 billion to the U.S. trade balance. At the same time this
technology like every other aspect of the economy finds itself in the midst of one
of today's most significant problem and debates, International and domestic
competition and reform of the health care system.
Some organization use a broad definition of medical device technology
encompassing most elements of health treatment, including pharmaceutical, medical
devices, and medical procedures. This thesis focuses more on the medical devices,
and diagnostic products. Medical devices range from relatively simple products,
such as surgical gloves, gowns and bandage, to highly sophisticated products such
as pacemakers. implacable defibrillator, laser, intraocular lenses fiberoptics, and
infusion pumps. Diagnostic products are those that detect or diagnose
specific diseases or injuries. They include X-ray machines, Computerized Axial
Tomography (CT/CAT) scanners, blood or urine tests, automated laboratory tests,
and home testing kits for pregnancy or a variety of illness.
By developing and marketing products of this kind, the health care technology
27
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industry has generated a strong economic performance for many years. To
illustrate, the commerce department identified four segments: (surgical and medical
instrument, surgical appliance and suppliers, electromedical equipment, and X-ray
apparatus and tubes - predicted to be the fastest-growing U.S. industry sectors for
1993 (table # 2).
There are many reasons for such success. First, medical device technology has
provided significant innovations in health care delivery in decades. With an aging
population, troubling conditions like cancer and heart disease, emerging new illness
such as Acquired Immune Deficiency Syndrome (AIDS) and growing concern over
good health and improved quality of life, such innovation has found a receptive
market. In addition, such products has proven to be successful in global market. As
industrialized and emerging nations attend to the growing health needs of
their population, this demand for products should continue to increase. The success
of the industry can also be attributed in part to its aggressive innovation and
intensive commitment to research and development (R&D). In 1991, for example
the industry invested 6.3% of sales in R&D (table # 3). This level far exceeded the
percentage invested in R&D by the aerospace and chemical industries, as well as
5.8% investment of the high-tech electronics industry. When compared to all U.S
industries, R&D spending in health technology industry was almost double the
national average.
Such innovation has allowed the industry to capture, and dominate, important
world markets. For the period 1987 to 1991, U.S. exports of medical products grew
more than doubling in total dollar value, reaching $7.9 billion in 1991 (figure 5.1).
Over the past decade, the purchasers of U.S. medical product exports have
remained largely the same (figure 5) In 1990, for example, the European
community, Japan and Canada received two-third of products exports, up slightly
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Table 2 Fastest Growing US Manufacturing industries in 1993
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Table 3 U.S. Research And Development R&D
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Figure 5 Purchaser of US Medical Products
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Figure 5.1 U.S Medical Exports
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from 1980 export levels. Imports of medical products into the U.S. grew at an
average annual rate of 12 percent for the period 1987 to 1991, reaching $4.1 billion
in 1991 (figure 6). The EC and Japan supplied 70 percent of US imports in 1990,
representing a decline from 1980 levels. This decline was primarily attributable to
changes in the level of imports from Germany, which fell from 35 to 25% of U.S.
imports during the period 1980 to 1990. In this same period, imports from Japan
increased from,18 to 24%. Combined imports from Germany and Japan totalled
$818 million and 794 respectively, which accounted for nearly half of total U.S.
imports of medical products in 1990.
In 1991 global production of health care technology totalled 70.9 billion. U.S.
production accounted for 48% of the total or $33.7 billion. These figure clearly
shows that competition is increasing and that unless the U.S. can achieve shorter
development time this industry could be in jeopardy.

3.2 Regulation of the Medical Device Industry
Because of the health care technology industry manufactures products for both
domestic and international use, it must comply with product safety, and
environmental regulation here and abroad. In the U.S. The food and drug
administration (FDA) regulates medical products for safety and effectiveness.
International regulation of health care technology varies by country, focusing
largely on safety.

3.2.1 United States Regulation (FDA)
The most direct form of medical device technology regulation in the U.S. is
conducted by the FDA and is designed to assure that all medical devices and
diagnostic products are safe and effective. This agency's regulatory duties fall into
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two general categories: review of a device before it reaches the market; and
postmarked control after it has been cleared by the FDA. The type of pre-market

review a medical device undergoes depends, in large part, upon the potential risk
it present to the patients. In cases where a device is not substantially equivalent to
a legally marketed device and pose significant potential risk, companies must often
gather extensive data, including results of testing in humans.
In cases where a product poses a less substantial risk, and is substantially
equivalent to a legally marketed device, a company must notify the agency it
intends to market the product and assure FDA that it meets certain basic standards.
Postmarked controls are designed to keep the agency informed of any potential
problems associated with a technology and to permit prompt action to address such
problems should they arise.

3.2.2 Product Classification
The degree of regulation a medical device undergoes largely depends, as noted
upon the degree of potential risk it poses to humans. After Congress passed the
Medical Device amendment of 1976, the legislation that introduced systematic premarket regulation of medical devices, the FDA classified devices into three
categories. Each of the categories, or classes, imposes an increasing level of control
over devices and establishes requirements that companies must meet before
introducing products onto the market.
- Class I: Products in this category represent devices that pose the least risk.
They include product such as simple elastic bandages, enema kits, and pipeting and
diluting systems for clinical use. Class I devices must meet certain general controls
that assure, among other things, that the product is not adulterated or misbranded,
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that it is properly labelled, that is manufactured in a manner to assure that the
finished device meets all the specifications, and that the FDA is notified prior to
marketing.
- Class II: Products in this category pose a moderate degree of risk and include
hearing aids, catheters and hypodermic syringes. In addition to meeting the general
control that apply to Class I products, Class II devices must meet any standards or
other special controls developed by the agency for that type of device.
- Class III: Products in this category pose the most significant potential risk and
are subject to the most stringent controls. Examples of devices in Class III include
cardiac pacemakers, extended-wear contact lenses, and replacement heart valves.
In addition to complying with the general controls that apply to both of the other
Classes of products, these devices must undergo detailed and often lengthy premarket evaluation to determine if they are safe and effective.

3.3 Product Approval Process
Regardless of the class a product falls into, FDA must conduct a pre-market review
of all medical devices before they can be introduced in the market. This is done
through detailed pre-market review of the device or a more routine pre-market
notification, depending upon the category into which the device has been classified.

3.3.1 Pre-market Notification
If a company intends to market a product that is "substantially equivalent" to an
earlier, legally marketed device, it can submit a pre-market notification application,
often called a 510(k) application, to the agency. This can be done for class I and
II and for devices in class HI which the FDA has not required a more detailed premarket approval (PMA) submission, as will be discussed later. The company must
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show that the device has the same intended use as the earlier device and that it
represents the same technological characteristics. If it represents different
characteristics, then the company must show that it is just as safe and effective as
the earlier device.
Once the company receives clearance from the FDA, it can market the product.
The fundamental behind pre-market notification is to expedite incremental
adjustments in health care technologies through the regulatory process. the
reasoning is that if a product represents a modification in a device already been
used, whose risk, reliability, and quality are already known, FDA generally needs
less information on the device before clearing it for marketing. This has
traditionally meant that 510(k) used to be processed relatively quickly often in less
than 90 days. Prompted by new legislation passes in 1990 as well as changes in
agency practices, however, FDA has recently begun to require more information
in 510(k) applications. In some cases the agency requires more extensive data
including data from product testing in humans. As a results of these changes, the
average total review time for pre-market notification applications has increased
steadily during the period fiscal year (FY) 1987 to 1991. Total review time grew
from 69 days in FY 1987 to 102 days in 1991, an increase of 48%. In addition the
total number of 510(k) decision issued by the agency, as well by the total number
of

510(k) clearance (in which the FDA agrees that a device is substantially

equivalent to an earlier version) are their lowest revels in recent years.

3.3.2 Pre-market Approval
FDA conducts even more rigorous pre-market review on devices that present
greater risk. These include Class III products, such as implantable devices, lifesustaining or supporting devices, or those which represent potentially unreasonable
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risk of injury or illness. Class III products also include all products that are not
substantially equivalent to an earlier device. That is, they represent a new kind of
technology whose risk and reliability are unknown for that type of device or use.
In these cases the medical device companies may be required to conduct a wide
range of physical, scientific, biological, and engineering tests on the device and
submit this information to the FDA in what is called a pre-market approval, or
PMA, application. In most cases.
Such applications must also include the results of product testing in humans.
Before humans tests can begin on devices that represent significant risks to
patients, however, the medical device company must obtain approval of an
institutional review board (IRB). A panel of medical experts at the institution that
will oversee the study. For these devices, the company must also submit a to the
FDA explaining among other things, how it will conduct the test, what type of
patients it will use, what results it expects, and what risks and precautions it
believes are involved. If the agency considers the request to be sound, it will grant
an investigational device exemption, IDE.
The IDE allows for the device to be used in patients for the purpose of
gathering data. As table 4 indicates the number of IDES received each year during
the period FY 1987 to 1991 has remained relatively constant, with a slight increase
in the years FY 1988 to 1990. Average FDA review time has experienced only
minor changes for the period as well. Once the study is complete, the company
must assemble, and present the data to the FDA in the PMA application. The
agency reviews the application carefully and may request additional information or
testing. Once the FDA is satisfied that the application shows that the products is
safe and effective, it approves the device for marketing.
The law requires that FDA evaluation of PMA must be completed within 180
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days. Because of the changing process within the FDA, however, review times
have increased significantly in more recent years. For example one measure of
review times, average lapsed time for FDA approvals, grew from 415 days in FY
1990 to 633 days in FY 1991, an increase of 53% for that year. At the same time
the number of devices approved by the agency declined by 43%. It can clearly be
seen that the FDA is a constraint is the development cycle of a new product.
fortunately in the solution to obtain shorter development cycle, offered by the phase
approach, discussed later, starting the interphase with FDA is done at almost the
beginning of the development cycle to allow for delay in dealing with the FDA.

3.4 The Importance of Accurate Documentation in the
Medical Device Industry
In the medical device industry, documentation is an integral part of the design and
manufacture of a product. The Food and Drug Administration (FDA) patrols the
medical sector to safeguard the public from hazardous devices. Good records allow
manufacturers to show the safety and efficacy of their products. Documents are
used internally to help companies keep track of products from beginning to end.
Other documents are required by the FDA to approve medical products for release.
The following paragraphs go into depth about the type of documents used by
medical companies to show and maintain the integrity of their products.
Internal company documents have various names but produce the same results.
They keep track of a medical device from conception to final use. Various forms
are utilized to inform key company personnel of new designs or changes to existing
design.
One such form is used by engineering to submit new designs. All pertinent
information about the design is included in the form. This information consists of
what the design is, why it is needed, and how will it be manufactured. Once this
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form is adequately filled out, it is circulated to the medical and regulatory experts
in the company. The medical experts determine if the product is useful in the
medical field. They also assist in determining whether biological tests and/or
clinical trials are required for the product. The regulatory experts check to see if
all regulations are adhered to. The approval from the medical and regulatory is an
essential ingredient to continue work on the project. The engineer can develop the
design during the time the form is being circulated, but if any issues arise, they
must be dealt with to successfully complete the project.
Another document sometimes necessary during the early stage of product
design is a patent. In order to apply for a patent, one of the important factors is
to keep track of all design work in a laboratory notebook. This notebook can be
used in court if someone else is applying for the same type of device. The
company law department or an outside consultant can assist in determine if a
device is patentable. Whether or not the device is patentable does not necessarily
effect if the device will go into production. Sometimes manufacturers decide not
to patent a device to keep it secret.
Regardless of what is decided, the flow of information continues. Once the
design is completed, other documents are generated to release and record that
design. A technical report is sometimes completed to record the design. The
technical report allows other people to gain from any new discoveries. A formal
release document also needs to be completed.

This document is a type of

engineering release form. The engineering release form includes all documentation
required to manufacture and sell the product. This paperwork can sometimes
include a very long list of documents. This list includes product drawings, product
specifications, packaging drawings, packaging specifications, manufacturing
drawings,

manufacturing specifications, sterilization specifications, quality
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assurance specifications, and any reference material such as memorandums and
initial design approvals. After all these documents are satisfactorily completed, the
engineering release form is sent to different functional areas for approval. These
functional areas consist of engineering, marketing, quality assurance, and
manufacturing. If any issues develop, they must be dealt with to get the product
to market.
If internal experts decide approval is needed from the FDA to get the product
to market, a pre-market notification, known as a 510(k), will have to be complete.

CHAPTER 4

QUALITY FUNCTION DEPLOYEMENT

4.1 Quality Function Deployment (Patient driven engineering)
"House of Quality," (HOQ) is a product development technique that had long been
used in Japan and that was gaining popularity in the US. Since 1988, over a
hundred U.S. firms have adopted the technique for part or all of their product
development activities. The House of Quality, which is part of Quality Function
Deployment (QFD), has evolved through use. The formal charting techniques have
been way to sophisticated market measurement, and firms have modified QFD to
work within their corporate culture. The same rationale can be used in the medical
device industry.

4.1.1 The House of Quality
Mishubishi's Kobe shipyard developed quality function deployment in 1972. Ford
and Xerox brought it to the U.S in 1986, and, in the last five years, it has been
adopted widely Japanese, U.S. and European firms. In some applications, it has
reduced design time by 40 percent and design cost by 60 percent while maintaining
and enhancing design quality. QFD helps an inter-functional team of people from
marketing, R&D, manufacturing and sales work together to focus on product
development. It provides procedures and processes to enhance
communication by focusing on the language of the customer. QFD uses four
"houses" to integrate informational needs. Applications begin with the HOQ, which
is shown conceptually in figure 7.
The team uses the HOQ to understand the voice of the patient and to translate
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Figure 7 Quality Function Chart
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it into the voice of the engineer. Subsequent houses continue to deploy the choice
of the patient through to parts characteristics and production requirements.

4.2 The Voice of the Patient (Through the physician)
Identifying the patient needs. The first task is to identify patient needs, which are
descriptions in the physician own words of the benefits they want the product or
service to provide. These needs are usually determined by personal interviews
and/or focus groups, which bring together six to eight physician for a facilitated
discussion. Physicians typically identify one hundred to four hundred needs,
including basic needs (what they just assume the product will do), articulated
needs, ( what they say they want the product to do) and excitement needs (which,
if they were fulfilled, would delight and surprise customers). However, it is
difficult for a team to work with so many patient needs simultaneously.
Structuring the needs. To manage the patients needs, the team has to structure
them into a hierarchy. The primary needs, also known as strategic needs, are
generally the five to ten top-level needs that set the strategic direction for the
product. "Ease of use" might be a primary need for a product. Secondary needs,
also known as tactical needs, are the elaborations of the primary need; each
primary need is usually divided into three to ten secondary needs. These needs
indicate more specifically what can be done to fulfill the corresponding strategic
or primary need. For example, the primary need " ease of use" might be described
further as " easy to say up" easy to operate," and "fast to use". In most cases, the
secondary needs are further subdivided into detailed tertiary needs. These indicate
specifically how the design team can fulfill the secondary needs.
Prioratizing the needs. Physician wants their needs fulfilled, but some needs
are more important than others. Prioritizing helps the QFD team balance the cost
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of fulfilling a need with the benefit to the patient. For example, if fulfilling two
needs is equally costly, then the need that is more important to the patient should
have higher priority. Theses priorities are normally determined through direct
market research with the physician. The first room of the House of Quality thus
contains the list of primary, secondary, and tertiary needs, in priority order. A
second room lists the priority or importance ratings.
Comparing Physician Perceptions. Other patient-related information appears
in another room in the house. Physician perceptions of how well the company's
current product and competitive products fulfill customer needs are useful for
guiding product design. By understanding which products fulfill patients needs best,
how well those customer needs are fulfilled, and whether there are any gaps
between the best product and the company's product, the QFD team can identify
goals and opportunities for products design. This information is obtained through
surveys of physician.

4.3 The Voice of the Engineer
Identifying Design Attributes. The other rooms in the house involve translating
patients needs into engineering concerns. The team needs to identify measurable
requirements.
- Design Attributes - that will fulfill patients needs. For example, design
attributes relating to ease of use might include "time to perform the task," "initial
set up time," and " time for a new operator to perform task." These attributes need
to be assigned physical measurement units (e.g., number of minutes) that then
become targets for an R&D or engineering design. However the attributes are not
product solutions. If solutions are specified too early, the R&D process becomes
constrained by existing solutions. New creative directions may be missed.
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Comparing Engineering Measures. Just as the team measured competitive
products with respect to customer needs, it now needs to compare competitive
products on the physical units specified by the design attributes. For example, the
time for a new operator to complete the task using each competing product must
be measured and compared with the others.
Developing the Relationship Matrix. the QFD team now judges which design
attributes influence which patients needs and how much. The idea is to specify the
strongest relationships while leaving most of the matrix (60 percent to 70 percent)
blank.
Developing the Roof Matrix. This matrix, symbolized in figure 7 by the crosshatched roof, quantify the physical relationships among the design attributes. For
example, if two design attributes are "speed of printing" and "quality of hard copy
output," then the roof matrix would indicate that improving one might degrade the
other. However, when possible, the design team will seek creative solutions that
improve both.
Making Other Estimate. In addition to the above, the team often estimates
cost, feasibility and technical difficulty for changes in each of the design attributes.
Developing a House of Quality can be time consuming. The team can spend a
number of months just preparing to begin design work. But that time should be
well spent. By identifying and quantifying customer needs, the team helps the
company avoid unnecessary and costly redesigns and other rework. The total
process should be shorter, less costly, and more effective.

4.4 The Importance of QFD in Concurrent Engineering
It is known that at the heart of CE are the capabilities of a company's technical
workers. But many companies have found that innovation, manufacturing, and
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quality can fit comfortably in Quality Function Deployment. QFD enhances Total
Quality Management (TQM) by emphasizing that quality in the medical device
industry is defined by the physicians and that is best achieved when a product or
service is designed to increase customer satisfaction. QFD shifts quality from a
"find and fix" mode to one of prevention. QFD is a team function; it's not just for
engineers.
Because design engineers in the medical device industry have traditionally been
isolated from the marketplace, they often have produced technically driven designs
that were unduly complicated and out of sync with the patient needs. Using QFD,
designers can convert customer needs into specific engineering requirements. A
patient driven QFD matrix can help concurrent engineering teams translate such
patient needs as " painless procedures". It is almost safe to predict that soon in the
medical device industry QFD training will be a condition for employment.

4.5 The Meaning of Quality to the Patient
We must remember that in the medical device industry, quality is much more than
meeting specifications. The physician point of view on quality is key. A survey
conducted by an american research company identified that the physician defines
quality in a medical device as reliability, durability, easy of maintenance for
reusable products, easy to use, a trusted brand name, and a low price with high
value.
The voice of the physician is the key element of Quality. From the perspective
of the physician, quality is not just quantitative, it is an assessment, a verdict, an
opinion. In short, it's something hard to pin down. The physician feels that the
patient will be willing to pay more for vquality if they believe that they are getting
more value. The proposed solution in the medical device industry will utilize the
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seven stage quality build-up approach. Instead of beginning in stage one with the
inspection function after production, audits, and problem solving activities, or the
next stages including quality assurance during production, using employee
education and training, product and process design optimization, and quality loss
function, the approach of choice is to work in stage one.
This is where the voice of the patient through the physician is defined and
carried throughout the value added chain, including the design of the part and the
design of the manufacturing process (discussed in the next chapter). to define the

voice of the patient in stage seven, we use as mentioned above QFD. This later
considers the voice of the patient throughout the total process, from design through
marketing. It's a technique that translates the customer requirements in all phases
of the product' development and use. QFD assures that the voice of the end user
is considered and his satisfaction assured.
As a designer in the medical industry, a high quality low cost segment of the
matrix is a good position to be in. The high-quality, high-cost position is for
selected high price market niches. The low-quality, high-cost segment will
obviously lead to a bad business position. And the low-quality, low-cost segment

is relegated to products like those coming from Japan 20 years ago (junk). Quality
does not have to cost money. In opposition, the lack of quality can be expensive.
The cost for non-conformance with quality specifications in the medical device
industry is equivalent to the astronomical figure of 25% of total sales. As one can

see QFD requires a change in attitude. Recognizing that quality defects are an
opportunity to improve the manufacturing process by analyzing causes as a team.
we have modern tools to optimize quality, improve the manufacturing process, and
work to improve the service and price of the product.

CHAPTER 5

PHASE APPROACH TO CE & DFM

5.1 A Dual Approach in the Development of a New Product
in the Medical Device Industry
In the medical industry one will encounter many difficulties to integrate design,
manufacturing, engineering and marketing without changing the basic approach to
management of new product development. The barriers to the integration can be
locations, background, budgeting practices and performance measurement system
to name a few. At present cross-functional teams are the most frequent way to cut
through barriers for integration of design and manufacturing.These teams should
have representative of design manufacturing marketing and quality.
However the team is only the beginning. Design for manufacturing (DFM) as
explained in chapter # 2 Quality Function Deployment (QFD) as describe in
chapter # 4 are necessary step to integrate design, manufacturing engineering, and
marketing. DFM, a design discipline, consist of management tools and techniques,
design principles and methodologies, and a philosophy of design integration and
optimization. Application of DFM aids smooth transition from development to
production where as QFD in the medical industry help to provide "better medicine".
However DFM, cross functional team and QFD are only three conditions necessary
for integration of design and manufacturing. The fourth and fifth are the a phase
approach in concurrent engineering and a product-process development approach.

5.2 The Phase Approach To Concurrent Engineering
Over a number of product development projects, a teams learns to apply a product
design in a way that reflects the company design philosophy. Individual team
50
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members learn how to contribute to the philosophy through the creation of many
informal communication networks. However, much of this learning is embodied in
these individual, and is lost to the team with their departure from the team. Further,
despite this design discipline, teams must still confront trade-off decisions on every
projects, among cost, features and delivery.
Pressures and constraints associated with these decisions often dictate many
aspect of product design, and make impossible to follow best practices or achieve
the best design. As such, teams need a step-by-step management procedure, or
approach, to discipline their interactions and to take members through these tradeoff decisions that are in virtually every new product development project. In the
medical industry the time is now for such a procedure. The phase procedure is
introduced to manage the integration of new product development activities. It is
to provide guidance to all divisions on identification and achievement of an
evolving system of technical and commercial objectives at each stage of the new
product development process. With the traditional financial control remaining in
place, the new procedure will facilitate divisions into expanding their views of
quality in new product development to include no defect, ease of manufacture and
operation and timeliness of market availability.
From the start, planning for quality will be an integral part of the product
development process. Development teams will catch and correct design deficiencies
earlier. There is far more leverage in eliminating such defect early in the
development process than later, when the product is in production or already in the
market. Quality also means reducing product component to their simplest form for
operation and manufacture. Unnecessary complexity will add extra cost and
reduced product and process reliability. Simplicity, on the other hand will lead to
improved manufacturability, market acceptance, and profitability. Finally, quality
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means timeliness of product availability to the customer. Throughout the new
product development the phase approach to CE will emphasize the achievement of
delivery schedule. Frequent milestone and formal reviews, one of the characteristic
in this approach will impress on the cross-functional team members the urgency of
their work.
These reviews also will allow team members to foresee the impact of delays
through the development process, and to control progress so that those dependent
on deliverables late in the process will have adequate to meet their deadlines. This
procedure will provide a basis for improving the performance of succeeding new
product development projects. It will highlight cost, time, and quality objectives for
each project and conducting formal reviews of progress at distinct stages. It will
also correct the difficulties of unsuccessful projects by placing an increased
emphasis on cost avoidance. The intention is to develop an environment in which
divisions would experience continuous learning and adaptation. A illustration of
this method as it applies to the medical device industry is described on Figure 8.
Within each of the step concurrent engineering technique could be applied.
Shortening the overall decision loops by doing certain activity parallel whenever
possible, and with a constant phase review process, are as important as shortening
the loops with each activity. Each activity on this chart has a series of sub-activity
which can be shortened by using CE and DFM technique.

5.2.1 The Phases of the New Product Development
In the medical device industry, the proposed phase approach will divide the new
product development cycle into five major phases: Project proposal,
Planning/Specification, Development, Evaluation & Manufacturing Implementation,
Start-up and Product Launch. The different feature of this procedure is a series of

Figure 8 The Phase Approach to DFM and CE
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reviews at each phase which occurred at the end of each development phase. In
general a project could fail review at any phase. In such a case it can be cancelled,

reworked, and again presented for review. or if the reasons for failure were not
perceived as major threats to the overall project, approval can be given to proceed
to the next phase with existing inadequacies.
Phase reviews will tell just how far a project is from its targets, and will
indicate what needs to be done to put it back on track before it become irreversibly
late and expensive. Phase reviews should be carried by a panel of senior manager"
appropriate to the level of importance of the project to the company". All functions
involved in the product development are to be represented at the reviews, including
marketing, design manufacturing, quality, customer service etc. The review panel
focuses on the product development schedule, product function, quality, cost, and
manufacturability. The panel will ensure that decisions made at earlier phase are
implemented and that the project core team (Figure 3 ) will anticipate and will deal
with down stream problems that may occur in volume manufacturing and the
market.

5.2.2 Responsibility of different Groups at Each Phase
A different department will assume responsibility for completion of each project
phase on time and to specification, marketing and design at earlier phases,
manufacturing later. The transfer of each responsibility will take place at each
phase, and should involve certified completion of project responsibilities by each
functional group involved. Under this approach in the medical device industry, a
department is to accept responsibility only when all preceding responsibilities are
discharged.
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5.3 Phase Description of New Product Development
Project Proposal Stage: The goal of the project proposal phase is to identify a new
business opportunity, which is reviewed at phase 0, the formal beginning of the
new product development process. Projects will go through two phases in this
stage: Knowledge prebuilt, and concept development. At the knowledge prebuild
phase, planning group, comprised of marketing and representatives, will match
market opportunities and available technology. From the many opportunities
identified each year perhaps a few with potential for developing into dominant
designs will be selected for concept development.
A full time product manager and product designer will then analyze the
market potential and concept, and then will develop draft specifications and plans
for project management (Figure 4). At phase zero, senior and divisional
management will evaluate the new business opportunity as a cost effective and
innovative technological solution that could developed with sustainable margins on
cost, revenues, and technology for a number of years.
The Planning/Specification Stage: Review of the product concept at phase one
will mark the need of the next major stage in the new product development cycle.
During this stage the product concept is defined, and marketing will set the context
with which integration of design and manufacturing will occur. Commercial
specification, outlining the functional and aesthetic features of the product, its price
range and its market launch program, including launch date will be developed.
These item will be commercial guideposts around which design and manufacturing
engineering will designed the product form, fit and functions. The ultimate
challenge for the development team will be to remain within these guideposts, and
launching a price competitive product on time while achieving the cost and
technological objectives set internally for the product. The review at phase one is

56
set up to answer the fundamental question:

do the designers know what the

customer actually requires? In the medical device industry a typical set of activities
in this phase will be a market assessment, patient/professional study, technological
review (patent search, license agreement) and a product/process specification.
The Development Stage: The development stage will end at phase 2. During
this stage, the project core team will develop the detailed specifications of what the
product will be, how it will perform, what it will look like, and how it will be
used. At this point most of the tool and technique of DFM including The axiomatic
approach to design as describe in chapter can be used. Here, product
manufacturability is a major focus of the engineer from two perspectives. First the
engineer will assess the readiness of the design for later prototype production and
testing. Second, the assessment of the product design for attributes that will both
avoid production line stoppages, rework costs, and aftersales problem, and also
increase safety, quality of workmanship, cost savings and process capability. The
focus on manufacturability will emphasize the design for cost avoidance through
product development in preference to cost improvement after product launch.

5.3.1 Application of DFM and CE in the Development Phase
The Activities of the development stage in a typical medical industry company are:
Prototype fabrication; evaluation clinical, marketing
Product/packaging design
Mfg Process capability development
Production process Equipment
Labelling
Technical documentation
Finalization of product specifications
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Finalization of product specifications
Engineering testing
Stability studies
Clinical
ISO/510k proposal and data collection.
With those activities DFM and CE tool and technique can be applied to only
some the rest are constraint that have to be faced because of the nature of the
industry.

5.3.2 Prototyping for Medical Device
One of the involvement of manufacturing in the design process should be the
fabrication of prototype. Prototypes should be built as soon as possible to find
problems not easily identified with computer modeling. Also functional testing with
prototype should be done as soon as possible. Many functional problems can be
identified and solved prior to the availability of final production hardware.
Moreover a small pilot line should be started as early as possible. Many
manufacturing process problems can b e solved utilizing early prototype. These
activities provide information that is critical to avoiding design changes and
assuring over all cycle time reduction.
Realizing additional cycle time reductions and quality improvement in the
future will necessitate increased integration not only of internal organizations but
of suppliers and customers as well. The efficiencies achieved through integration
of design and manufacturing should be enhanced whenever possible by including
suppliers and customers in the design process. Early and continuous involvement
by manufacturing, marketing, supplier, and customer will lead to products that meet
and exceed customer expectations.
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5.3.3 Engineering Testing of Medical device
To assure an extremely high quality level product performance an a short product
cycle, the device testing has to be done on a prototype design level. Existing test
equipment capable of performing standardize test should available ( ex: if the
company makes needles, Tinous Olsen test apparatus should be readily available
to the test the stiffness of the cannula.) This equipment should be set up in the lab
to simulate the manufacturing line test equipment. Early decoction of problem will
allow time to modify design and improve manufacturing quality before volume
production begin. This simplified testing of the device will improved the quality
of the product at significant cost savings.

5.3.4 Manufacturing Process Capability Development
Compliance, the accommodation of manufacturing error, should be designed into
the medical device product to avoid excessive assembly force, rework and scrap.
The relation of the manufacturing tolerance to the part specification limits is called
process capability index. The reason for using this tool in the medical industry is
simply that by focusing on the process capability index, there exist a commitment
up-front to measuring and controlling manufacturing variability through statistical
process control (SPC) tools and methods such as control charts. In addition it is an
excellent tool for negotiating with and communication with suppliers to set the
appropriate quality level and expectations.
The process capability index focuses on communication between the design
development, and manufacturing parts of the organization. By managing the
relationship of design tolerance to manufacturing specifications, it shifts attention
away from a possible adversarial relationship between design and manufacturing
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to a more constructive one where the common goal of achieving a particular index
level facilitates negotiations and cooperation in a new medical product
development. Medical device product usually are manufactured through materials
and processes that are inherently variable. Design engineers specify materials and
process characteristics to a nominal value, which is the ideal level for use in the
product. The maximum range of variation of the product characteristic that will still
work in the product determines the tolerances about the nominal value. This range
is expressed as upper and lower specifications limits (USL and LSL).
The manufacturing process variability is usually approximated by a normal
probability distribution, with mean of "U" and a standard deviation of "a". The
process capability is defined as the full range of normal manufacturing process
variation measured for a chosen characteristic. Assuming normal distribution,
99.74% of the process output lies between -3σ and +3σ.
A properly controlled manufacturing process should make products whose
output mean characteristic or target are set to the nominal value of the
specification. This is easily achieved through control charts. If the process mean
is not equal to the product nominal value, it can be shifted by recalibrating
production machinery or inspecting incoming raw material characteristics.
The variation of the manufacturing processes (process capability) should be
well within the product tolerance limits. The intersection of the process capability
and the specification limits determines the reject level. Process capability can be
monitored using control charts.

The manufacturing process variability can be

reduced by using optimized equipment calibration and maintenance schedules,
increased material inspection and testing, and by using design of experiments to
determine the best set of process parameters to reduce variability.
The classical design for manufacturing conflict of interests between design and
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design engineers would prefer the narrowest possible process capability, so that
they can specify the maximum tolerance specifications to ensure the proper
functioning of their product. In contrast, the manufacturing engineers would prefer
the widest possible tolerance specification, so that they can continue to operate the
largest possible manufacturing capability to reduce the amount of rejects. The
process capability index is a good arbiter of the two groups' interests.
The idea manufacturing process should produce clones of the production by
performing replication of all fabrication and assembly materials, processes and
movements. However, this can never be achieved, because of variations in
manufacturing. As the production machines and processes continue to turn out the
product, the characteristics of materials and tools in the process change as they are
being consumed. Materials hardness can change from the supplier for different lots
and still be within specifications; machinery, fixtures, and tools wear out; and even
though they can be replaced, recalibrated, or resharpened in an ideal maintenance
schedule, they can still result in variation in the product. Employees can be
properly trained to perform production tasks, but will slightly alter production
operations because of fatigue or human error. Conditions beyond the control of the
plant management could result in variability, due to environmental and weather
changes or changes in suppliers, which are further multiplied by their subsuppliers'
variations.
Some or all of these conditions can cause product variability, which when
added up at each level of production could cause some of the product to become
defective even though it is within acceptable limits at each stage of production.
This reject rate will adversely effect the quality, and hence the cost, of the product.
There are two ways to increase the quality level of new products: either
increase the product specification limit and allow manufacturing variability to

σ
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increase the product specification limit and allow manufacturing variability to
remain the same yet product fewer defects; or reduce manufacturing variability by
improving the quality level of materials and processes through inspection, increased
maintenance, and performing design of experiments to determine variability sources
and counteract them. The ratio of the interaction of these two sources of rejects
is called the process capability index, Cp: (Juran Quality Handbook)
Cp =

specification width (or design tolerance)/process capability

where
USL = upper specification limit
LSL = lower specification limit
= manufacturing process standard deviation
The Cp value can predict the reject rate of new products by using normal
probability distribution curves. A high Cp index indicates that the process is
capable of replicating faithfully the product characteristics, and therefore will
produce products with high quality.
The utility of the Cp index is that it shows the balance of the quality
responsibility between the design and manufacturing engineers. The quality level
is set by the ratio of the effects of both. The design engineer should increase the
allowable tolerance to the maximum value that still permits the successful
functioning of the product, and the manufacturing engineer should minimize the
variability of the manufacturing process by proper material and process selection,
inspection, calibration, and control, and by performing design of experiments

5.3.5 Production Process
Focus on the production process technology is important. How can an organization

Figure 9 Spinal Needle Insert Mold Sterile
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analyze its current activities and develop its unique approach to a mare change
oriented, flexible, quick reflex business. The suggested approach for the medical
device industry is called the work flow analysis. It is centered on diagraming or
charting the path taken by new product programs during development and
introduction and quantifying the activity effort been applied. Work flow analysis
involves determining and plotting in sequence the existing steps in a particular
process. Insight comes from using a technique of viewing each action step in term
of input/action/output such as the output of a given action constitute the input of
the next action. Bringing into view the numerous loops, sequences, approval chains
and rework item that exist in the process of a medical device product.
Recognizing the complex actual path is a necessary first step in dealing with
it. The next step is to make a concerted effort to reduce the detail times. A helpful
method is to visualize the usefulness of activities in contributing value to the final
product. Those activities that stand out as having low value should be questioned
for elimination or combination. Certainly time elapse with no contribution does not
add value. Another approach is that any activity that one can perform in an
alternate or better way at less cost or time is not adding value and should be
replaced by a better alternative. Using the work flow analysis an organization
alignment and grouping is created where the work output of each work group is
organized to be fully accomplished as input of the next group. A majority of
support work can be moved offline or in parallel so that only necessary action are
performed on the main line resulting in shortening the total development cycle.
Example of this concept is illustrated in figure 9.

CHAPTER 6

TOOLS OF DFM

6.1 Tools of Concurrent Engineering
The traditional product development process is a series of specific tasks, often
performed by a different group in the organization. The phases of product
development (Ideas, Conceptual Design, Detailed Design, Analysis, Drafting and
Manufacturing) must each be largely completed before the next begins. Since the
late 1960s and early 1970s there have been software tools available to help with
each stage of the product development process. Current software tools, known as
second generation tools are aimed at automating a specific function. For example,
a CAD tool helps drafters to draft better or mechanical engineers to design better,
or manufacturing engineers to generate improved tools paths or to create efficient
process plans. Because each second generation tool is a discrete product and has
its own database, there can be no sharing of information between phases of the
product development. Each task must be completed before passing off to the next
phase.
This forces product development into running sequentially. In the traditional,
serial product development process, parallel activities are often integrated only after
they are completed. And that is when problems arise. For example, for a new
device (safety Syringe) various subsystem are developed by individual groups: one
group work on the lubrication of the barrel another on the barrel itself, still another
on the plunger, etc. Although it looks like this approach saves time because
development works takes place simultaneously, the pieces of ten fail to work when
it comes time to integrate and test. Then redesign begins. And redesign is both
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expensive and time consuming, especially if it takes place late in the product
development process.
A study by Dataquest looked at the typical cost to make changes during
different phases in the development of a major medical device products. A change
that might cost $1000 in the design stage will cost $10,000 in design testing
$100,000 during process planning, $1,000,000 during test production. With the
traditional approach to product development, making changes is too difficult, even
early-on in the development process. Second generation tools do not accommodate
change. There is actually a negative incentive for change in sequential product
development, even if changes in design could ultimately produce a better product.
Consider for example a thin walled, molded plastic part which is well into the
product development process. The parts and assemblies have been modeled on the
CAD system, analyses performed, drafting created, molds modeled and analyzed,
and some tool paths created. At this point the design engineer determines that there
is a different material that would allow for a thinner part, an overall better quality
design at a lower cost.
However the task of going back into all the CAD tools to update geometry,
parts, assemblies, and drawings, create new finite element models and rerun the
analyses, and to update the tool paths, mold information, etc. is overwhelming and
a barrier to changing the design, even though the original is not the most
competitive or most efficient design. Compounding the problem with second
generation tools are multiple data structures at each stage in product development.
These introduce the potential for loss of design integrity. Consider the situation
from the molded plastic part for example above, where updates are started, but
somehow not completed. Perhaps the drawing has been modified, but not the parts
geometry or assemblies; the result is that potential fit problems in the assembly go
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undetected, or there is incorrect geometry in the part. Maybe the analyses have not
been re-run, or the molds and tooling not updated. The wrong prints may be used
for tooling, leading to fit problems manifested only during the manufacturing or
prototype stage. Or there may be failures in the fields requiring a product recall.
All of these problems with serial approach with second generation tools
translate into lost dollars, lost work time and lost quality. There is no way that a
company can hope to meet a target of first to market , cost effectively with a high
quality product under these conditions. Even with the recent hardware and software
advances providing more affordable and powerful hardware, memory advanced
graphics capabilities, and telecommunication networks for distribution of
information and communication, the current second-generation software tools don't
go quite far enough. They are bound to a sequential, serial product development,
by their multiple data base architectures and a general unfriendliness to change.
Second generation tools limits a company's ability to achieve competitive leverage
in today's medical device industry environment. Both second generation tools and
sequential product process do not promote fast cycle time for high- quality products
developed in a cost-efficient way.

6.2 The Third Generation Tools Approach to Product Development
To increase product quality and reduce cost while simultaneously improving the
speed of product development requires a fundamental change in the development
process itself and in the automation tools used for product development. That
change is the third-generation approach an overlapped, concurrent, parallel, team
product development process. And what makes this radically new approach to
product development possible are the third generation automation tools. Thirds
generation product development encourages a team approach and as such reflects
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the early inputs of the various functions and ensure communication throughout the
entire development cycle. For example, early participation by manufacturing
ensures that manufacturing requirements and constraints are understood at the
outset and taken into consideration in the design. Not only does this help engineers
to avoid problems, costly mistake, and retooling, but also to manage effectively
their machine tool and shop floor resources.
Overlapping, concurrent functions provide for and overall compression of the
product development process, and hence, a faster time-to-market. And while
overlap shortens the product development cycle, it also allows far the allotment of
more time in certain phases. And more time spent considering design iterations or
examining interference or fit problems or optimizing tool paths and mold flow and
manufacturing process plans translates into a higher-quality product. The ability to
fine tune the product model in the design phase also promotes cost savings by
eliminating unnecessary mistakes and products delays at the a same time that
quality of the product is being improved. What makes this type of product possible
is a tool which incorporates input from all engineering disciplines through the use
of a single database. It is because of the unified database that changes, key and
necessary changes are propagated automatically to all project team members, all
other engineering disciplines and phases. Everyone's work is updated, and all
deliverables reflect the change, drawings, models, assemblies, manufacturing tools
paths, mold flows, etc.
Reconsider the example of the thin walled molded plastic part where the
design engineer determines late in the development process that there is a better
material available. With only the second generation tools at hands, the designer
opts to abandon a redesign because the task is intimidating. With third-generation
tolls, however, the change is simple and straightforward, and updates of drawings
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models and analyses are automatic and complete.

6.3 Philosophical Tool of DFM
The development and use of design methodologies that help the design team
achieve an optimized design solution as describe in chapter 2 is an important part
of the DFM approach. table # 1 provides a selected list of DFM methodologies
or tools and indicates where they might fit into the proposed DFM process. Use
of these design methodologies helps promote the objectives of DFM by hiding the
design team in making better informed design decisions and providing systematic
procedures that help ensure that all aspects of product function manufacture, and
operational support are considered from the start.
An axiomatic approach to design, explained in detail earlier is based on the
belief that fundamental principles or axioms of good design exist and that use of
the axioms to guide and to evaluate design decisions leads to good design. By
definition, an axiom must be applicable to the full range of design decisions and
to all stages, phases, and levels of the design process. Design axioms cannot be
proven, but rather must be accepted as general truths because no violation or
counterexample has ever been observed.
A study of many successful designs by several individuals in 1977 led them
to propose a set of hypothetical axioms for design and manufacturing. Analysis and
refinement of the initial axioms has shown that good design embodies two basic
concepts. The first is that each functional requirement of a product should be
satisfied independently by some aspect, feature, or component within the design.
The second is that good designs maximize simplicity; in other words, they provide
the required functions with minimal complexity.
Use of design axioms in design is a two-step process. The first is to identify
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the functional requirements (FRs) and constraints. Each FR should be specified
such that the FRs are neither redundant nor inconsistent. It is also useful in this
step to order the FRs in a hierarchical structure, starting with the primary FR and
proceeding to the FR of least importance. Once the functional requirements and
constraints are specified for a given product or design problem, the second step is
to proceed with the design, applying the axioms to each design decision. Each
decision should be guided by the axioms and must not violate them.
Application of the design axioms to the analysis and design of products and
manufacturing systems is not always easy or straightforward. Because the axioms
are quite abstract, their use requires considerable practice as well as extensive onthe-job design and manufacturing experience and judgment. After reading this
thesis, the axiom of manufacturing will be easy to understand.

6.4 Simplification of the Axioms of Manufacturing as Design Tools
DFM guidelines are systematic and codified statements of good design practice that
have been empirically derived from years of design and ► manufacturing experience.
Typically, the guidelines are stated as directives that act to both stimulate creativity
and show the way to good deign for manufacture. If correctly followed, they
should result in a product that is inherently easier to manufacture. Various forms
of the design guidelines have been stated by different authors, a sampling of which
follows:
1)

Design for a minimum number of parts

2)

Develop a modular design

3)

Minimize part variations

4)

Design parts to be multifunctional

5)

Design parts for multiuse
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6)

Design parts for ease of fabrication

7)

Avoid separate fasteners

8)

Minimize assembly directions; design for top-down assembly ( B-D
Pulsitainer, our design example)

9)

Maximize compliance; design for ease of assembly

10)

Minimize handling; design for handling and presentation

11)

Evaluate assembly methods

12)

Eliminate or simplify adjustments

13)

Avoid flexible components

DFM guidelines show the way, but do not replace the talent, innovation, and
experience of the product development team. They must also be applied in a
manner that maintains and, if possible, enhances product performance and
marketing goals. Design guidelines should be thought of as 'optimal suggestions,'
which, if successfully followed, will result in a high-quality, low-cost, and
manufacture-friendly design. If a product performance or marketing requirement
prevents full compliance with a particular guideline, then the next best alternative
should be selected.

6.4.1 Illustration of DFA as a Design Tool
The design for assembly (DFA) method was developed by G. Boothroyd and P.
Dewhurst while at the University of Massachusetts (Amherst). Details of the
methodology are presented in Design for Assembly - A Designer's Handbook.
Based largely on industrial engineering time study methods, the DFA method
developed by Boothroyd and Dewhurst seeks to minimize cost of assembly within
constraints imposed by other design requirements. This is done by first reducing
the number of parts and then ensuring that the remaining parts are easy to
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assemble. Essentially, the method is a systematic, step-by-step implementation of
the DFM guideline numbers 1, 7, 8, 9, and 10.

6.4.2 The Taguchi Method: A Tool Necessary to Meet the Requirement
in the Medical Device Industry
The Taguchi method addresses the problems associated with determining robust
design by using statistical design of experiment theory. Robust design implies a
product designed to perform its intended function no matter what the
circumstances. In particular, the Taguchi method seeks to identify a robust
combination of design parameter values by conducting a series of factorial
experiments and/or using other statistical methods. Termed parameter design by
Taguchi, this step establishes the mid-values for robust regions of the design factors
that influence system output. The next step, called tolerance (allowance) design,
determines the tolerances or allowable range of variation for each factor. The midvalues and varying ranges of these factors and conditions are considered as
variance factors and are arranged in orthogonal tables to determine the magnitude
of their influences on the final output characteristics of the system. A narrower
allowance will be given to noise factors imparting a large influence on the output.
In establishing the tolerance or allowance range for a particular parameter,
Taguchi uses a unique concept defined as a loss function. In this approach, loss
is expressed as a cost to either society (the customer) or the company that is
produced by deviation of the parameter value from design intent. Because any
deviation from design intent produces a loss, allowance or permissible deviation
should be determined based on the magnitude of the cost associated with this loss.
The concept of loss and other Taguchi concepts provide valuable insight into
quality and the role design plays in determining the quality of a product or system.
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6.4.3 A Process Driven Manufacturing
Process driven design seeks to ensure that parts and products are correctly designed
to be produced using a particular production process or method. Design
requirements for a given process are often stated in the form of design guidelines
and rules of thumb. Typically, these guidelines are highly specialized for a
particular industry, process implementation, plant, or equipment installation within
a particular plant. Making the designer aware of these process requirements and
constraints early in the design process, before concepts are finalized and lines are
put irreversibly on paper, is a goal of design for manufacture. Design tools that
help ensure product/process conformance and enable process-driven design can
generally be classified as either process specific or facility specific.
Process specific DFM involves the design of parts to be manufactured using
particular methods or processes such as casting, forging, injection molding, and
stamping. Typically, these tools facilitate systematic application of specialized
process knowledge in the form of codified statements of design guidelines and rules
to the design of parts to be made using a particular manufacturing process or
method. Examples include design for casting, design for injection molding, and
design for total stamping.
Facility specific DFM tools facilitate correct design of products intended to
be manufactured using highly specialized or unique advanced manufacturing
facilities. Such tools, which could be aptly described as "designer toolkits,"
provide design rules, physical examples and models, various CAD design aids, and
other specific information about a specialized manufacturing facility in a readily
usable form to the designer.
Development of manufacturing facility specific DFM is, at present, in its
infancy and is likely to advance very quickly as the relevance of this approach
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becomes more widely recognized. Typical applications that could benefit greatly
from the designer toolkit approach include such diverse situations as flexible
assembly and manufacturing system concepts.
A major barrier to DFM is usually time. Design and manufacturing engineers
are typically operating under very tight schedules and are, therefore, reluctant to
spend time learning and using DFM approaches. Computer aided DFM helps
simplify the effort and shortens the time required to implement DFM on a daily
basis. Computer-aided DFM also enables the design team to consider a multitude
of product/process alternatives easily and quickly. "What-if" optimization allows
each alternative to be refined and fine tuned. Together, these capabilities greatly
increase the probability of identifying the most desirable solutions during the early
stages of design. When properly implemented, computer-aided DFM has the
potential to vastly improve the quality of early product/process decisions and
thereby enhance the design team's ability to design for effective quality, cost, and
delivery. Another major benefit of computer-aided DFM is the way it fosters team
building and the team approach.
A variety of proprietary computer aided DFM software packages is currently
available. In addition, considerable effort is being directed toward the development
of new computer-based and/or computer aided DFM methodologies.

6.5 The Importance of a Good Software Selection
A good third generation software package (PROengineer for example) will
increased design productivity by 400 percent. A typical plastic one piece medical
device molded part would take 40 hours of design time with our previous wire
frame system. Now it can be done in 8 to 10 hours with a third generation
software tool.
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But the third generation software has done more than shorten the design cycle
for many companies. It has also shortened product manufacturing time and
improved product quality. And, when combined with superior graphics capability,
produced a marketing tool which, in the words of one customer, "knocked their
socks off."
It recommended that medical device company acquired the software after
collaborating with their mold makers and vendors. Many design experts using

Pro/Engineer explains that they can both be looking at 3D CAD systems at the
same time, as their vendor.

They selected the third generation tool approach

because it is able to demonstrate a CNC connection with their equipment
manufacturing controllers. Since this vendor builds many of our molds, their
decision that was a large factor in our evaluation process.

Many major manufacturer of plastic parts, medical device, automotive parts,
and pharmaceutical products, using a third generation tool proved to be the right

decision. With software, they are able to do a lot of the development right on the
computer rather than creating expensive prototypes. For example, It's assume we're
designing a very, very intricate hinge for a dispensing cap, containing brand new

ideas and technology. We can zoom in on it, and look at the cap from every angle.
We can flex it, rotate the hinge elements and see exactly where it's going to go.
We can make a lot of changes right in the computer, optimizing the design upfront.
A year ago, we would have made a guess at what we thought it should look

like and made a mold.

Six weeks later, we would have had something that

probably didn't work. We would make some changes and go through the whole
process all over again. We no longer waste time, effort, and money that way.
The consensus is to install an ENGINEER and a MOLDESIGN and Flow
analysis version of the software used to mesh models for finite element and mold
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flow analysis. FEA is used to optimize product weight vs. strength, to minimize
cycle time, and maximize productivity of the mold. The cycle is related to molten
masses, so "if we can thin area down, we can speed up the manufacturing process."
A fast manufacturing process and error-free design are critical since the typical
production run for caps can run into the millions. A tooling error can be disastrous
in terms of cost and customer service.
Some of the third generation out there are virtually flawless. One reason we
will be so responsive to customer needs is because most of those software files can

be used to make error-free stereolithography models and prototype molds. Often,
we have service bureaus mail the SLA models direct to the customer, so they can
have the part within 48 hours.

We are also going directly from 3D files to the mold, without going through
the drawing stage. That's one of the things that used to slow us down, creating the
blueprint. The mold maker really does not need a print. He uses the same for his
cutter path to create the mold. Now, we just sent floppy disks to the mold maker.
This third generation software will allow the Medical device manufacturer to

be customer responsive in other ways. One way is by delivering visualizations of
a new product within three hours of the customer's initial request. With this tool,

we can construct a solid model of a new cap within a couple of hours with a good
workstations, one of which is equipped with superior Graphics. This configuration
allows us to generate photo quality visuals on the screen, visuals so good that you
can't tell it's not a real object.

We output the solid model off the screen and deliver them to the customer.
At the same time that we send the photo-real images, we might very well get a
stereolithography model made. The product visuals can be delivered within three
hours and the stereolithography model within 48 hours of the time we receive the
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customer request. The fast response to customer requests has been the only
deciding factor in gaining recent new business but he does know it has greatly
improved the way they develop and sell new products.

CHAPTER 7

A DFM EXAMPLE

7.1 B-D PulsitainerTM (Blood containment Device) A DFM example
The best way to illustrate the concept of Concurrent Engineering and Design For
Manufacture as applied to the medical industry is to analyze an actual project
where the tools and techniques describe in this thesis were utilized. In this example,
although every single tool or methodology that can be used in the design of a new
product was not used. The one used illustrated the idea of Design for Manufacture
and Concurrent Engineering technique in the medical device industry.
Marketing and Engineering personnel began to think about this design as a
solution to a very serious problem in the health care industry. Health care workers
are exposed every day to enormous danger because they are constantly in contact
with patients who have transmitable diseases. Needle sticks and contacts to blood
occur during medical procedures every day in the health care environment. That is
the reason that medical device companies like Becton Dickinson and many others
choose to adopt a strategy focusing on designing products that make the procedures
in question safe for the individuals (nurses, doctors) performing them. Possible
nosocomial transmission of blood-borne pathogens is a serious concern for health
care workers and patients. Fears about physician-to-patient transmission of HIV
have been heightened by reports of HIV transmission in medical practices. The risk
of transmission from patient to health care worker after needle-stick injury has been
examined in several recent reports. Fears persist because of the potential
devastating consequences of infection. The device in question, B-D Pulsitainer
Blood containment device is used during Invasive Radiologic Procedures. It is an
77
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attachment to the needle used in the performance the procedure.

7.1.1 Rationale
The use of a device or system to encapsulate spurting of pulsating blood following
arterial punctures seems to have been first reported 1988. With the increasing
awareness of blood borne pathogens, and the increasing risk of infection to health
care workers, there has been a number of preventive methods and techniques
reported. Recently, there has been a growing concern with regards to procedures
performed by both radiologists and cardiologist. However, unlike conventional
methods to prevent percutaneous infection by needle sticks, the subject device
would reduce the chance of exposure by containing spurting blood. Recent
regulations promulgated by the Occupational Safety and Health Administration
(OSHA) are relevant. Part of the Universal Precautions require that procedures
involving blood shall be performed in such a manner as to minimize splashing,
spattering and generation of droplets of blood.
While certain methods and products exist to aid in this effort, it is important
that the basic technique not be compromised. Any new device should be
compatible with the users technique. It should have the ability to collect, contain,
and dispose of blood, with a minimum of effort. This should result in less exposure
and a generally safer procedure.

7.2 An Interfunctional Product Development Team
QFD stressed that product development is more successful if there is good
communication among all the people involved in designing, building, and
delivering the product to the customer. A team drawn from marketing, customer
service, sales , engineering, R&D, manufacturing, and management was put
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together for this project. This team stayed together throughout the development of
the new BD Pulsitainer Blood containment device and was involved in all the
market research and all the technical design. In this way, engineering and R&D had
first hand exposure to all the physician and patients needs; marketing, customer
service, and sales understood the technology behind the product, how to use the
technology, and what improvements where likely to be feasible in the future: The
product was designed for cost-effective manufacture. All strategic decision were
made with full knowledge of the physician and the technology and with the team
support.

7.3 The Voice of the Physician in the Development
of the Pulsitainer
The marketing personnel got in touch with all physician currently performing
radiographic procedures. Through a combination of focus groups and telephone
interviews, customers (radiologist and cardiologist) were ask to describe their
experiences, and what is critical during the procedure, and how they made product
decision. When a physician mentioned a need or experience, the interviewer probed
the physician until he or she gained a deep understanding of that need from the
physician perspective. The interviews were recorded, transcribed, and analyzed
carefully. Team members looked for any and all needs that were mentioned,
including basic needs, which they assume that any blood containment device should
satisfy, and articulated needs, which the physician specifically raised. They also
sought to identify any excitement needs. Those that if fulfilled would have
delighted and surprised the physician but that were not yet available with any blood
containment device. The findings were as follows:
1- The visualization of arterial access by clear blood spurt of the side holes in
the collection chamber (articulated need).
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2- Pre-loading the guidewire should be easy (exciting need)
3- The tactile feel of the physician cannot be compromised (articulated need)
4- Finally the blood should be contained after the procedure (basic need)
These four functional requirement were obtained after talking to many doctors.
Most of them would not consider buying the product if requirements # 3 and # 4
were compromised. The questionnaire was done to design the best product that we
know the customers would buy. Everything that was done from there was based on
those requirements. This constituted the Quality Function Deployment part of the
project.

7.4 PulsitainerrM Cost Target
The next step was to establish a cost target. The customer even though they would
buy this product were not willing to pay a lot for it. All the physician felt that even
though the product is useful in preventing blood borne pathogen accident it does
not simplify the procedure. Moreover they felt that the whole procedure was bloody
anyway, therefore the elimination of the spurting of the blood during the initial
stick does not constitute a big deal. All the aforesaid reasons were important to put
a price tag on the product. Currently, Arrow sells a similar kind of product for
$7.50, and Cook sells theirs for $8.50. Our target is to sell the B-D PULSITAINER
for about $3.50. Also it is our intention to provide a superior product. Incidently,
those same doctors that we questioned indicated to us that the competitor products
did not meet the functional requirement. The competitor's products were designed
without consulting the end user prior to designing them.
Now that functional requirement and cost target were set. It was possible to
draft and applied a phase implementation approach as describe in Chapter 5. figure
10 represents the phases in which the project was carried out..

Figure 10 PULSITAINER Phase Implementation
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PHASE # I
a)

A 510k was submitted to the FDA early in the project to give them enough
time to analyze our proposal.

b)

At the same time a Product Device Notification (PDN) was submitted to our
Medical division requesting approval of the design and approval of the
materials and components involved. For instance, the toxicity level of all the
material were tested to prevent the company from producing a device that
could endanger the life of the patient.

c)

Also at the same time, a patent search was initiate to make sure that our
design was not infringing any other patents.

PHASE # II
a)

Our initial design concept was then analyze with care using the DFM tool
to come up with the best design for manufacture without compromising the
functionality requirements

b)

We then begun to work with our supplier for the components. We welcome
their suggestions as long as that they did not compromised the functionality
requirements for our product design.

c)

We tried our best to use existing approved components and materials. The
syringe barrel that we used is a standard item, the vent plug material was preapproved for production in a different product. The plastic tubes were extruded
by one of our manufacturing plant with a pre-approved resin.

d)

After all the parts where designed, and the materials selected, in cooperation
with our machine shop we build a series of show-and-tell prototypes. Those
were shown to many physicians and to the marketing group. They were all
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satisfied with the way that the prototype looked. It addressed all of their
concerns. They only had small comments pertaining to the size and weight.
e) Our next test was then to make actual working prototype to be tested in a
laboratory environment. An in-vitro model simulating an actual human heart
rate was built to simulate the pulse that the device will see. Using the model,
the device was tested for leakage. We even had a physician come and tested
a our device using our in vitro model.
PHASE #III
At that point, all documents were generated and releases in an Engineering
release order.
PHASE # IV
Finally, another engineering order was released to release the product for market.
The difference between this Engineering order and the previous one is that in the
latter all the cost information were included whereas in the
previous one only documents and drawings were released.
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